Name | N-(2-Hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide |
---|---|
Synonyms |
DprE1-IN-1
AZ7371 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-4-pyrimidinyl)methyl]-6-methyl- N-(2-Hydroxyethyl)-1-[(6-methoxy-5-methyl-4-pyrimidinyl)methyl]-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide AZ-7371 |
Description | DprE1-IN-1 is a potent DprE1 inhibitor, with ic50 of 10 nM, also inhibits PDE6, with IC50 of 6 uM.IC50 value: 10 nM [1]Target: DprE1in vitro: DprE1-IN-1 demonstrats efficacy in a rodent model of tuberculosis, making it promising for further development.[1]in vivo: The pharmacokinetic profile of DprE1-IN-1 as a representative of the series in mice, rats, and dogs was determined after i.v. and oral dosing. DprE1-IN-1 shows oral bioavailabilities of 86% and 100% in rats and dogs, respectively. The oral exposures of DprE1-IN-1, assessed in infected animals, shows AUCs ranging from 166 to 240 μM · h, and free plasma concentrations were maintained above the MIC for 10 to 24 h. [2] |
---|---|
Related Catalog | |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 691.6±55.0 °C at 760 mmHg |
Molecular Formula | C18H21N5O3 |
Molecular Weight | 355.391 |
Flash Point | 372.1±31.5 °C |
Exact Mass | 355.164429 |
LogP | 1.37 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.650 |
Storage condition | 2-8℃ |